Trial CLL17 will examine a new option for the first-line therapy of chronic lymphocytic leukemia (CLL) compared with established treatments. The trial therapy consists of a combination of ibrutinib and venetoclax; this treatment is given for a limited period and both active substances are taken orally.

For more information on where and how this trial is conducted, consult the trial website.